Felicia Gorcyca
Known title: Chief People OfficerCIK: 0001865529
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Keybanc Raises LifeStance Health Price Target to $15. Keybanc maintained an Overweight rating on LifeStance Health and raised its price target to $15. This follows the company's recent Q2 2026 earnings call. The stock is currently trading near the middle of its 52-week range, with an average analyst target of $14.40.
Transaction History
| WSC | ▲ Buy | Option Exercise | 1,594 | — | 2/24/2026 | View on chart |
| WSC | ▼ Sell | Tax Withholding | 505 | $12K | 2/24/2026 | View on chart |
| WSC | ▲ Buy | Option Exercise | 1,156 | — | 2/22/2026 | View on chart |
| WSC | ▼ Sell | Tax Withholding | 366 | $8K | 2/22/2026 | View on chart |
| WSC | ▼ Sell | Tax Withholding | 366 | $13K | 2/22/2025 | View on chart |
| WSC | ▲ Buy | Option Exercise | 1,155 | — | 2/22/2025 | View on chart |
| LFST | ▼ Sell | Open Market | 2,638 | $14K | 6/13/2022 | View on chart |
| LFST | ▲ Buy | Grant | 76,446 | $0 | 4/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
WillScot Holdings: Fund Review and Analyst Target Cuts
A recent quarterly portfolio review by the Worldwide Responsible Global Alpha Paris-Aligned Fund highlighted WillScot Holdings. Both Citigroup and Baird have lowered their price targets to $21, a drop from the previous range. The changes suggest analysts are more cautious about the company’s valuation. Investors may want to note the revised outlook as they assess future performance.
WillScot Holdings: Fund Review and Analyst Target Cuts. A recent quarterly portfolio review by the Worldwide Responsible Global Alpha Paris-Aligned Fund highlighted WillScot Holdings. Both Citigroup and Baird have lowered their price targets to $21, a drop from the previous range. The changes suggest analysts are more cautious about the company’s valuation. Investors may want to note the revised outlook as they assess future performance.